At the IGTP TODAY
The Program of Advanced Therapies (PATH) of IGTP held an event on 5 November to showcase capabilities across the Can Ruti Campus, foster collaboration between research groups, clinical professionals and companies, and address challenges in bringing advanced therapies into clinical practice.
IGTP coordinates one of the selected projects and is involved in two others, focusing on the identification of biomarkers, treatment resistance and anti-tumour immune responses. Together, the three initiatives have received nearly €1.1 million in funding.
A study led by researchers from IGTP and BST has developed and validated a manufacturing platform for extracellular vesicles that meets pharmaceutical quality requirements, marking a key step towards their clinical application
An IGTP study, published in Movement Disorders, highlights the potential of platelets for investigating biomarkers of Parkinson's disease progression. Some of the changes were also observed in an independent cohort of 15 patients with early-onset sporadic Parkinson's disease.
IGTP’s CARE Program held its fourth Annual Meeting on 22 October. The event brought together researchers and healthcare professionals to share projects and research activities, meet the new groups joining the program and review the work carried out so far.
A clinical trial involving 240 adolescents aged 12 to 17 has shown that HIPRA's COVID-19 vaccine, BIMERVAX®, administered as a booster dose, induces a broad immune response against different SARS-CoV-2 variants, comparable to that observed in adults and sustained for at least one year. The study, published in Pediatrics, was led by IrsiCaixa, IGTP, VHIR and HIPRA as part of the European RBDCOV project.
_edited_1792056506.png)
A European study involving GCAT-IGTP has identified an association between greater exposure to air pollution, particularly PM10 particles, greater temperature variability and higher blood glucose levels in people without diabetes. The findings highlight the importance of studying environmental factors together and improving air quality in the context of climate change.
IGTP held a new event in collaboration with EATRIS, the European infrastructure for translational medicine, focusing this year on the role of artificial intelligence in biomarker research and precision medicine.
The Innomed community visited IDNEO to learn about its capabilities in device development, digital technologies and MedTech solutions. The visit aimed to identify opportunities for collaboration between research teams and industry to advance healthcare innovation projects.
A project led by Federico Fondelli, researcher at the IGTP, has been selected in the 2026 CaixaImpulse Health Innovation call promoted by the "la Caixa" Foundation. The project will receive €49,000 to advance the development of a new cell therapy strategy aimed at specifically restoring the immune system's tolerance to myelin in people with multiple sclerosis.
